HOME >> BIOLOGY >> NEWS
New drugs for bad bugs

GAINESVILLE, Fla. -- Call it a chemical crystal ball. A new approach to predict whether a drug in development is likely to work and which dose is best could get antibiotics to market faster and more cheaply, say University of Florida researchers.

In recent years, scientists worldwide have sounded the alarm: There simply aren't enough drugs to combat bad bugs. Bacteria are increasingly adept at outwitting the traditional antibiotic arsenal.

Yet designing and testing new antibiotics can be a maddeningly slow and costly process -- if pharmaceutical companies even bother, says Hartmut Derendorf, chairman of the department of pharmaceutics at the University of Florida College of Pharmacy. Many would rather invest in compounds aimed at patients with chronic conditions such as high cholesterol or diabetes, not in drugs designed to be used for a week or two and then stopped once an infection clears, he said.

Now UF researchers have devised a patent-pending method that combines testing of various drug concentrations at the site of infection with a series of laboratory analyses and mathematical models designed to streamline drug development.

The method helps better determine which drugs are worth studying in people and at which dose, avoiding the typically lengthy and expensive trial-and-error approach that can take years.

"About one new antibiotic a year is approved," said Derendorf, who will discuss the technique Saturday (March 5) at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics in Orlando. "That's certainly not enough. Even more worrisome, there are very few in the pipeline right now. Meanwhile, the requirements are getting longer and longer, and this is a huge dilemma with the recent discussion about Vioxx. That's created some doubt in the approval procedure. I think we have to come to a reasonable expectation here in terms of the balance between benefits and potential harm. The worries I
'"/>

Contact: Melanie Ross
ufcardiac@aol.com
352-392-2624
University of Florida
4-Mar-2005


Page: 1 2 3 4

Related biology news :

1. MIT model could predict cells response to drugs
2. New target for HIV/AIDS drugs and vaccine discovered
3. Modified mushrooms may yield human drugs
4. UGR researchers design an alternative to blood test to detect drugs in the body
5. Could fungal collection hold the key to new life-saving drugs?
6. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
7. Scientists develop new drugs to fight colon and breast cancer more effectively
8. Anti-inflammatory drugs interact with HRT, and more
9. Generic biologic drugs unlikely to offer significant savings
10. Stem cells provide new tool for studying disease and identifying ALS drugs
11. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drugs for bad bugs

(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... -- According to a new market research ... Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, Defense ... 2020", published by MarketsandMarkets, defines and segments the Physical ... The global PIAM Market is estimated to grow from ... at a CAGR of 14.9 % from 2014 to ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
(Date:9/2/2015)... Virginia , September 2, 2015 ... of the winners of the 2015 BeHEARD science challenge, ... that offers rare disease researchers, access to the latest ... use its drug repositioning and pathway analytics capability to ... Wylder Nation Foundation in the study of Niemann-Pick Disease ...
(Date:9/2/2015)... SOUTH SAN FRANCISCO, Calif. , Sept. 2, 2015 ... announced that Bonnie H. Anderson , president and ... Global Healthcare Conference on Wednesday, September 16, 2015 at ... . The live audio webcast ... http://investor.veracyte.com . The webcast will be available shortly ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories ... be attending Pharma Ed Resources upcoming educational seminar and training session on Extractable ... this timely conference will provide Updates & Case Studies on the Latest Compliance ...
(Date:9/1/2015)... ... 2015 , ... Spirax Sarco , the leader in products and services ... Anytime. This platform, offering unique online ordering capabilities, is only available to Spirax ... on to Spirax Sarco Anytime and within minutes you can be making your purchase. ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Spirax Sarco Announces New Features to Anytime Platform 2
Cached News: